Fax: (901) 521-9005
Role of temozolomide after radiotherapy for newly diagnosed diffuse brainstem glioma in children
Results of a multiinstitutional study (SJHG-98)
Article first published online: 24 NOV 2004
Copyright © 2004 American Cancer Society
Volume 103, Issue 1, pages 133–139, 1 January 2005
How to Cite
Broniscer, A., Iacono, L., Chintagumpala, M., Fouladi, M., Wallace, D., Bowers, D. C., Stewart, C., Krasin, M. J. and Gajjar, A. (2005), Role of temozolomide after radiotherapy for newly diagnosed diffuse brainstem glioma in children. Cancer, 103: 133–139. doi: 10.1002/cncr.20741
- Issue published online: 17 DEC 2004
- Article first published online: 24 NOV 2004
- Manuscript Accepted: 9 SEP 2004
- Manuscript Received: 2 AUG 2004
- Cancer Center Support (CORE) Grant from the National Institutes of Health. Grant Number: P30 CA21765
- Schering-Plough Institute
- American-Lebanese-Syrian Associated Charities
- diffuse brainstem glioma;
The role of chemotherapy in the treatment of children with newly diagnosed diffuse brainstem glioma is uncertain. In the current study, the authors tested the efficacy of temozolomide treatment after radiotherapy (RT) in this setting.
Patients ages 3–21 years were eligible for the current multiinstitutional study. An optional window therapy regimen consisting of 2 cycles of intravenous irinotecan (10 doses of 20 mg/m2 per day separated by 2 days of rest per cycle) was delivered over 6 weeks and was followed by conventionally fractionated RT. The 5-day schedule of temozolomide (200 mg/m2 per day) was initiated 4 weeks after RT and was continued for a total of 6 cycles. The pharmacokinetics of temozolomide and its active metabolite, 5-(3-methyltriazen-1-yl)imidazole-4-carboxamide (MTIC), were analyzed during Cycles 1 and 3.
Thirty-three patients (median age at diagnosis, 6.4 years) were enrolled. Of the 16 patients who received window therapy, 6 had irinotecan treatment discontinued due to clinical progression (n = 5) or toxicity (n = 1); the remaining 10 experienced disease stabilization after 2 cycles. All patients completed RT (median dose, 55.8 gray). Twenty-nine patients received a combined total of 125 cycles of temozolomide. Grade 3/4 neutropenia and thrombocytopenia occurred in 33% and 29% of all temozolomide cycles, respectively. In approximately one-third of the cycles, dose reduction was required due to myelosuppression. No correlation was demonstrated between temozolomide/MTIC exposure and myelosuppression at the conclusion of Cycle 1. All patients died of disease progression (median survival, 12 months). The estimated 1-year survival rate was 48% (standard error, 8%).
The administration of temozolomide after RT did not alter the poor prognosis associated with newly diagnosed diffuse brainstem glioma in children. Cancer 2005. © 2004 American Cancer Society.